Citizens Financial Group Inc. RI Has $8.80 Million Holdings in Pfizer Inc. $PFE

Citizens Financial Group Inc. RI trimmed its position in Pfizer Inc. (NYSE:PFE) by 5.9% in the third quarter, HoldingsChannel.com reports. The firm owned 345,509 shares of the biopharmaceutical company’s stock after selling 21,826 shares during the period. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $8,804,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Curio Wealth LLC lifted its holdings in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,098 shares during the period. Harbor Asset Planning Inc. acquired a new position in Pfizer in the second quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer during the second quarter valued at approximately $30,000. Darwin Wealth Management LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $32,000. Finally, Evelyn Partners Asset Management Ltd bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla says Pfizer expects a consumer-sized obesity market comparable to the post‑Viagra boom — signals management is prioritizing obesity as a multi‑year growth engine. Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
• Positive Sentiment: Pfizer completed a ~$10B Metsera acquisition and plans a big push on obesity drug development in 2026 — strategic M&A to accelerate pipeline and commercial scale in GLP‑1/obesity space. Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
• Positive Sentiment: New trial data: Pfizer’s cancer combo showed stronger tumor shrinkage versus standard care in advanced colorectal cancer — supports oncology franchise growth and potential label/market share gains. Pfizer Cancer Combo Drug Shows Strong Tumor Shrinkage in Colorectal Cancer Trial
• Positive Sentiment: Pfizer advanced a global Phase 2/3 lung cancer combo and launched a Phase 3 head‑to‑head colorectal study (PF‑08634404) — meaningful pipeline catalysts if readouts are positive. Pfizer Advances New Lung Cancer Combo in Global Phase 2/3 Trial Pfizer’s New Colorectal Cancer Trial Puts PF-08634404 Head-to-Head With a Market Standard
• Positive Sentiment: Positive new data on the Braftovi regimen adds to oncology momentum and incremental revenue potential. Positive new data on Pfizer’s Braftovi regimen
• Neutral Sentiment: Pfizer presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for detail but no single headline catalyst. Pfizer Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Coverage of partnerships with data/AI vendors (Tempus) and sector ETFs highlights industry tailwinds — supportive macro backdrop but not an immediate stock mover. Tempus AI (TEM) Stock: Why Big Pharma Is Betting Big on This AI Platform This ETF Is Proof That the Healthcare Rebound Is Real
• Negative Sentiment: UBS initiated coverage with a Neutral rating and $25 target, citing lingering revenue uncertainty tied to major drugs (~$15–20B exposure) — a near‑term cap on upside and reason for investor caution. UBS Likes Pfizer’s MTSR Obesity Deal but Stays Neutral on PFE

Wall Street Analyst Weigh In

PFE has been the topic of several recent analyst reports. Scotiabank started coverage on Pfizer in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Bank of America reduced their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Citigroup initiated coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a report on Wednesday, December 17th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $27.88.

Pfizer Stock Down 0.8%

Shares of NYSE:PFE opened at $25.28 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market cap of $143.71 billion, a P/E ratio of 14.69 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company’s 50-day moving average price is $25.28 and its two-hundred day moving average price is $24.97.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.